Insomnia Therapeutics Market Size Worth $3.45 Billion by 2025: Grand View Research, Inc.

Wednesday, November 1, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, November 1, 2017 /PRNewswire/ --

The global insomnia therapeutics market is expected to

reach USD 3.45billion by 2025, according to a new report by Grand View Research, Inc. The market is primarily driven by the presence of patented molecules, potential clinical pipeline candidates, rising stress level, and
increase in geriatric population who find it difficult to fall asleep. Increase in prevalence of insomnia &awareness about this condition and availability of safer drugs are anticipated to fuel revenue growth.

     (Logo: )

Insomnia is estimated to affect approximately 35% of the global population. Different patterns of the condition include difficulty in sleep initiation and maintenance, which is generally accompanied with frequent awakenings awakening too early with trouble sleeping again. Long-term insomnia can hamper everyday life, which may result in nonproductive work hours. If left untreated, this condition may lead to severe depression and nervous breakdown of the patient.

Factors influencing insomnia therapeutics market growth include rising stress level, presence of patented molecules in the market, potential drugs in clinical pipeline, introduction of technologically advanced medical devices, and growing geriatric population. Growing awareness about the impact of sleep deprivation on everyday life is anticipated to increase adoption rate of various treatments for insomnia, which is expected to lead to revenue growth of the insomnia therapeutics market.

Currently, widely adopted treatment options for insomnia include generic non benzodiazepines and antidepressants even though other novel agents such as orexin antagonists and melatonin antagonists are available in the market. Launch of Eisai's Lemborexant is expected to cater to unmet medical needs in this segment and fuel growth of this market over the forecast period. According to United Nations (UN) report in 2015, population in the age group of 60 years and above is projected to grow by 56% and is expected to reach around 1.4 billion by 2030. These statistics indicate the growing geriatric population. Since this population base is more susceptible to sleep deprivation, the demand for insomnia therapeutics is anticipated to increase.

Browse full research report with TOC on "Insomnia Therapeutics Market Analysis By Treatment Type [Devices, Drugs (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists)], By Sales Channel, And Segment Forecasts, 2014 - 2025" at:

Further Key Findings From the Report Suggest: 

  • North America held majority of the share in 2016 due to increase in awareness about diseases, growing geriatric population, and high adoption of therapeutics for treatment.
  • The U.S. dominated North America owing to the presence of largest sleep-deprived population and use of patented drugs for treatment.
  • Japan is the second largest market after the U.S. Asia Pacific is expected to be the fastest growing market due to the presence of emerging economies like China & India and launch of new drugs.
  • Some of the key players are Takeda Pharmaceutical Co. Ltd.; Vanda Pharmaceuticals; Merck & Co, Inc.; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Mylan N. V.; Sumitomo Dainippon Pharma Co., Ltd.; Sanofi; Paratek Pharmaceuticals; and Ebb Therapeutics.

Browse related reports by Grand View Research: 

  • Medical Document Management Systems Market -
  • Spinal Fusion Bone Graft Substitutes Market -
  • C-reactive protein Testing Market -
  • Cryosurgery Market -

Grand View Research has segmented the insomnia therapeutics market on the basis of treatment type, sales channel, and region: 

  • Insomnia Therapeutics Market Treatment Type Outlook (Revenue, USD Million, 2014 - 2025) 
    • Drugs
      • Benzodiazepines
      • Nonbenzodiazepines
      • Antidepressants
      • Orexin antagonist
      • Melatonin antagonist
      • Others
    • Devices
  • Insomnia Therapeutics Market Sales Channel Outlook (Revenue, USD Million, 2014 - 2025) 
    • Prescription
    • Over-the-Counter(OTC)
  • Insomnia Therapeutics Market Regional Outlook (Revenue, USD Million, 2014 - 2025) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • Japan
      • China
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa

Read Our Blog By Grand View Research:

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email:


SOURCE Grand View Research, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store